(Q24288978)

4

object named as

G R Cutter

0 references

author name string

J Petkau

1

0 references

S C Reingold

2

0 references

T R Fleming

5

0 references

M D Hughes

6

0 references

D H Miller

7

0 references

H F McFarland

8

0 references

J S Wolinsky

Multiple Sclerosis Journal

9

0 references

language of work or name

English

0 references

publication date

July 2008

0 references

published in

0 references

volume

14

0 references

issue

6

0 references

page(s)

770-8

0 references

cites work

Why most published research findings are false

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

The role of MRI as a surrogate outcome measure in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Surrogate end points in clinical trials: are we being misled?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Surrogate endpoints in clinical trials: definition and operational criteria

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2692530

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

30 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

The emerging role of MRI in multiple sclerosis and the new diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Surrogate Endpoints And FDA’s Accelerated Approval Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Predictors of relapse rate in MS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507088104

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18535021

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18535021

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458507088104

1 reference

4823760

4823760

1 reference

1 reference

1 reference